Generic Injectables Market Research Report, by Product Type (Monoclonal antibodies, Cytokines, Insulin, Vaccines), Container (Vials, Ampoules, Premix, Prefilled syringes), Application (Oncology, Anaesthesia, Anti-infectives, Cardiovascular), Distribution Channel (Hospital pharmacy, Retail pharmacy, Drug stores, Online stores) – Global Forecast Till 2027
ID: MRFR/HC/6043-HCR | February 2021 | Region: Global | 100 pages
Market Scenario
The global generic injectables market is projected to grow significantly over the forecast period. It is estimated that the global generic injectables market is expected to register a CAGR of ~13% during the forecast period of 2018–2023.
Generic injectable is referred to as biologics that are used for the treatment of various disease and has same drug/ active ingredients as that of its respective branded versions. However, the inactive contents of the drugs can be varied. The increasing prevalence of chronic and infectious disease along with the advancement in research and academic initiatives by the private and governmental sector is expected to drive the market growth.
For instance, as per the World Health Organization (WHO) 2015, over 38 million death occur globally due to non- communicable chronic diseases annually, which is propelling demand for development of low-cost generic vaccines. Moreover, nearly 86% of infants are vaccinated the rest remain unvaccinated leading to a death toll of about 2-3 million infants annually. Shortage of branded sterile injectable has further led to the adoption of generic injectable which in-turn is expected to restrain the market growth.
Segmentation
The global generic injectables market is segmented on the basis of product type, container, application, distribution channel, and end user.
The generic injectables market, by product type is categorised into monoclonal antibodies, cytokines, insulin, vaccines, and others.
On the basis of container, the market is segmented into vials, ampoules, premix, and prefilled syringes.
Based on application, the generic injectables market is segmented oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular, and others.
The generic injectables market, by distribution channel is categorised into hospital pharmacy, retail pharmacy, drug stores, and online prescription stores.
On the basis of region, the global generic injectables market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The generic injectables market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Generic injectables Market Share (%), by Region, 2017
Sources: Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, National Institutes of Health
It is projected that the Americas dominated the global generic injectables market owing to the growth of the market in the North American region. This is largely attributed to the factors such as an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs. Even though the generic injectable industry has operations across the globe, majority of largest manufacturers produce a large volume of generic injectable in the U.S. Moreover, in the U.S. over 70% of hospital patients receive generic injectable drugs, which is further pushing the demand for generic injectable in North America.
Europe is currently holding a considerable amount of market share in the generic injectables market owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. For instance, in June 2017, Baxter signed an agreement with Dorizoe for life sciences company manufacturing generic sterile injectable. This alliance is anticipated to develop more than 20 generic injectable products including cardiovascular and oncolytic medicines.
Asia-Pacific was projected to be the fastest growing region for the global generic injectables market. This owes to the infrastructural development and increase in outsourcing of research activities to the contract research organizations (CROs) at relatively low cost in this region. For example, the Sun Pharma’s acquisition of Pharmalucence in 2014 that resulted in benchmarking sales of generic sterile injectable.
The Middle East and Africa holds the least share in the global generic injectables market due to the presence of economically diverse countries, and less initiatives taken by the government.
Global Generic injectables Market, by Product type
- Monoclonal antibodies
- Cytokines
- Insulin
- Vaccines
- Others
Global Generic injectables Market, by Container
- Vials
- Ampoules
- Premix
- Prefilled syringes
Global Generic Injectables Market, by Application
- Oncology
- Anaesthesia
- Anti-infectives
- Parenteral nutrition
- Cardiovascular
- Others
Global Generic Injectables Market, by Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online prescription stores
- Others
Global Generic injectables Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Global Generic injectables Market, Key Players
- Novartis AG (Sandoz International GmbH)
- Baxter
- Fresenius SE & Co. KGaA
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals plc
- Sanofi
- Biocon
- Reddy’s Laboratories
- Aurobindo Pharma
- Zydus Cadila
- GlaxoSmithKline plc
- AstraZeneca plc.
Intended Audience
- Pharmaceutical & Biopharmaceutical companies
- Biotechnological companies
- Government institutions
- Research and Development (R&D) companies
- Medical research laboratories
Frequently Asked Questions (FAQ) :
The global generic injectables market is expected to exhibit a strong 13% CAGR over the forecast period from 2018 to 2023.
The increasing prevalence of chronic and infectious diseases is driving the demand for effective generic injectables.
Key types of generic injectables include monoclonal antibodies, cytokines, insulin, vaccines, and others.
The Americas is likely to dominate the global generic injectables market.
Leading players in the generic injectables market include Novartis, Baxter, Sanofi, Biocon, and Zydus Cadila, among others.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Overview
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Generic injectables Market, by Product Type
6.1 Overview
6.2 Monoclonal antibodies
6.3 Cytokines
6.4 Insulin
6.5 Vaccines
6.6 Others
Chapter 7. Global Generic injectables Market, by Container
7.1 Overview
7.2 Vials
7.3 Ampoules
7.4 Premix
7.5 Prefilled syringes
Chapter 8. Global Generic injectables Market, by Application
8.1 Overview
8.2 Oncology
8.3 Anaesthesia
8.4 Anti-infectives
8.5 Parenteral nutrition
8.6 Cardiovascular
8.7 Others
Chapter 9. Global Generic injectables Market, by Distribution Channel
9.1 Overview
9.2 Hospital pharmacy
9.3 Retail pharmacy
9.4 Drug stores
9.5 Online prescription stores
9.6 Others
Chapter 10. Global Generic injectables Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
Chapter 12. Company Profiles
12.1 Novartis AG (Sandoz International GmbH)
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Baxter
12.3 Fresenius SE & Co. KGaA
12.4 Mylan N.V.
12.5 Teva Pharmaceutical Industries Ltd.
12.6 Hikma Pharmaceuticals plc
12.7 Sanofi
12.8 Biocon
12.9 Dr. Reddy’s Laboratories
12.10 Aurobindo Pharma
12.11 Zydus Cadila
12.12 GlaxoSmithKline plc
12.12 AstraZeneca plc.
12.14 Others
Chapter 13 Appendix
LIST OF TABLES
TABLE 1 GLOBAL GENERIC INJECTABLES MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL GENERIC INJECTABLES MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 7 GLOBAL GENERIC INJECTABLES MARKET, BY REGION, 2020-2027(USD MILLION)
TABLE 8 NORTH AMERICA: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 10 NORTH AMERICA: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 11 NORTH AMERICA: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 12 NORTH AMERICA: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 13 US: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 14 US: GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 15 US: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 16 US: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 17 US: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 18 CANADA: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 19 CANADA: GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 20 CANADA: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 21 CANADA: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 22 CANADA: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 23 SOUTH AMERICA: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 24 SOUTH AMERICA: GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 25 SOUTH AMERICA: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 26 SOUTH AMERICA: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 27 SOUTH AMERICA: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 28 EUROPE: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 29 EUROPE: GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 30 EUROPE: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 31 EUROPE: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 32 EUROPE: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 33 WESTERN EUROPE: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 34 WESTERN EUROPE GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 35 WESTERN EUROPE: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 36 WESTERN EUROPE: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 37 WESTERN EUROPE: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 38 EASTERN EUROPE: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 39 EASTERN EUROPE GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 40 EASTERN EUROPE: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 41 EASTERN EUROPE: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 42 EASTERN EUROPE: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 43 ASIA-PACIFIC: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 44 ASIA-PACIFIC GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 45 ASIA-PACIFIC: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 46 ASIA-PACIFIC: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 47 ASIA-PACIFIC: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA: GENERIC INJECTABLES MARKET, BY PRODUCT TYPE, 2020-2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET, BY CONTAINER, 2020-2027 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA: GENERIC INJECTABLES MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA: GENERIC INJECTABLES MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA: GENERIC INJECTABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 SEGMENTATION FOR GLOBAL GENERIC INJECTABLES MARKET
FIGURE 3 MARKET DYNAMICS FOR GLOBAL GENERIC INJECTABLES MARKET
FIGURE 4 GLOBAL GENERIC INJECTABLES MARKET SHARE, BY PRODUCT TYPE, 2020 (%)
FIGURE 5 GLOBAL GENERIC INJECTABLES MARKET, BY CONTAINER, 2020 (%)
FIGURE 6 GLOBAL GENERIC INJECTABLES MARKET SHARE, BY APPLICATION, 2020 (%)
FIGURE 7 GLOBAL GENERIC INJECTABLES MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%)
FIGURE 8 GLOBAL GENERIC INJECTABLES MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 NORTH AMERICA: GENERIC INJECTABLES MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 EUROPE: GENERIC INJECTABLES MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: GENERIC INJECTABLES MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: GENERIC INJECTABLES MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL GENERIC INJECTABLES MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 NOVARTIS AG: KEY FINANCIALS
FIGURE 15 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 16 NOVARTIS AG: GEOGRAPHICAL REVENUE
FIGURE 17 BAXTER: KEY FINANCIALS
FIGURE 18 BAXTER: SEGMENTAL REVENUE
FIGURE 19 BAXTER: GEOGRAPHICAL REVENUE
FIGURE 20 FRESENIUS SE & CO. KGAA: KEY FINANCIALS
FIGURE 21 FRESENIUS SE & CO. KGAA: SEGMENTAL REVENUE
FIGURE 22 FRESENIUS SE & CO. KGAA: GEOGRAPHICAL REVENUE
FIGURE 23 MYLAN N.V.: KEY FINANCIALS
FIGURE 24 MYLAN N.V.: SEGMENTAL REVENUE
FIGURE 25 MYLAN N.V.: GEOGRAPHICAL REVENUE
FIGURE 26 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS
FIGURE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE
FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL REVENUE
FIGURE 29 HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS
FIGURE 30 HIKMA PHARMACEUTICALS PLC: SEGMENTAL REVENUE
FIGURE 31 HIKMA PHARMACEUTICALS PLC: GEOGRAPHICAL REVENUE
FIGURE 32 SANOFI: KEY FINANCIALS
FIGURE 33 SANOFI: SEGMENTAL REVENUE
FIGURE 34 SANOFI: GEOGRAPHICAL REVENUE
FIGURE 35 BIOCON: KEY FINANCIALS
FIGURE 36 BIOCON: SEGMENTAL REVENUE
FIGURE 37 BIOCON: GEOGRAPHICAL REVENUE
FIGURE 38 DR. REDDY’S LABORATORIES: KEY FINANCIALS
FIGURE 39 DR. REDDY’S LABORATORIES: SEGMENTAL REVENUE
FIGURE 40 DR. REDDY’S LABORATORIES: GEOGRAPHICAL REVENUE
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.
